“RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalization,” Peter Marks, director of the FDA’s Center ...

The Food and Drug Administration (FDA) has approved the drug Beyfortus for the prevention of respiratory syncytial virus (RSV) in babies and toddlers.

"In older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis," the FDA said.

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

"These RSV vaccines are based on 21st century science and technology designed to overcome the shortcomings of previous efforts six decades ago," the FDA's Dr. David Kaslow said in opening the meeting.

The FDA expanded the approval of the GSK vaccine in June to include adults ages 50 to 59 at risk of RSV-LRTD due to underlying conditions. The Moderna vaccine is approved for people ages 60 and ...

RSV is the second-leading cause of death during the first year of a newborn’s life, second only to malaria. Globally, about 120,000 babies die from RSV every year.

The FDA has approved the first-ever vaccine for respiratory syncytial virus, or RSV, completing an elusive quest that has been decades in the making.

Pfizer’s RSV vaccine for pregnant people: The FDA said it has agreed to review Pfizer’s vaccine candidate, RSVpreF, for approval and set an action date for August.

Pfizer’s RSV vaccine for pregnant people: The FDA said it has agreed to review Pfizer’s vaccine candidate, RSVpreF, for approval and set an action date for August.